Full Press Release Details
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors.
IDYA
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
Key Takeaway: IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
Price reaction · baseline $28.01 (2023-09-08 close) · clean, no other IDYA news in the window
day 0 close · peak
+3.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma